B. Casu*

发表

Orthogonal analytical approaches to detect potential contaminants in heparin

R. Langer, Zhenqing Zhang, R. Linhardt, 2009, Proceedings of the National Academy of Sciences.

Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events

Robert Langer, Robert J Linhardt, Benito Casu, 2008, Nature Biotechnology.

Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.

B. Perly, G. Torri, M. Petitou, 1990, Carbohydrate research.

Structure of Heparin and Heparin Fragments

B. Casu, B. Casu*, 1989, Annals of the New York Academy of Sciences.

1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.

M. Petitou, B. Casu, U. Lindahl, 2003, Biochimie.

Structure and biological interactions of heparin and heparan sulfate.

B. Casu, U. Lindahl, B. Casu*, 2001, Advances in carbohydrate chemistry and biochemistry.

Structure and biological activity of heparin.

B. Casu, B. Casu*, 1985, Advances in carbohydrate chemistry and biochemistry.

The Impact of Heparanese and Heparin on Cancer Metastasis and Angiogenesis

R. Sasisekharan, I. Vlodavsky, B. Casu, 2006, Pathophysiology of Haemostasis and Thrombosis.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

B. Barlogie, J. Shaughnessy, L. Suva, 2007, Blood.

Infrared absorption and raman scattering of sulfate groups of heparin and related glycosaminoglycans in aqueous solution

B. Casu, A. Perlin, F. Cabassi, 1978 .

Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans.

M. Petitou, M Petitou, B. Casu, 1988, Trends in biochemical sciences.

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.

M. Petitou, J. Choay, J. Lormeau, 1983, Biochemical and biophysical research communications.

Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.

G. Torri, B. Casu, A. Naggi, 2010, Matrix biology : journal of the International Society for Matrix Biology.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Benito Casu, Annamaria Naggi, Israel Vlodavsky, 2007, Current pharmaceutical design.

SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis

F. Zunino, R. Sanderson, C. Pisano, 2011, Clinical Cancer Research.

P‐selectin‐ and heparanase‐dependent antimetastatic activity of non‐anticoagulant heparins

L. Borsig, G. Torri, I. Vlodavsky, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.

G. Torri, B. Casu, A. Naggi, 2007, Seminars in thrombosis and hemostasis.

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

L. Nissinen, A. Wärri, M. Borgenström, 2007, Seminars in thrombosis and hemostasis.

Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting*

G. Giannini, C. Pisano, G. Torri, 2005, Journal of Biological Chemistry.

Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models

R. Sarid, R. Abramovitch, I. Vlodavsky, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Cancer Therapy : Preclinical SST 0001 , a Chemically Modified Heparin , Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase / Syndecan-1 Axis

F. Zunino, R. Sanderson, C. Pisano, 2011 .

Heparanase, heparin and the coagulation system in cancer progression.

R. Sasisekharan, G. Torri, B. Brenner, 2007, Thrombosis research.

Structure and Active Domains of Heparin

B. Casu, B. Casu*, 2005 .

Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate.

Benito Casu, Marco Guerrini, G. Torri, 2004, Current pharmaceutical design.

Structural features and binding properties of chondroitin sulfates, dermatan sulfate, and heparan sulfate.

B. Casu, B. Casu*, 1991, Seminars in thrombosis and hemostasis.

"Linkage region" sequences of heparins and heparan sulfates: detection and quantification by nuclear magnetic resonance spectroscopy.

M. Iacomini, G. Torri, B. Casu, 1999, Analytical biochemistry.

Nuclear magnetic resonance studies of polysaccharide structure and interactions

B. Casu, B. Casu*, 1985 .

Infrared spectra of amylose and its oligomers

B. Casu, M. Reggiani, B. Casu*, 2007 .

The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.

R. Zeisig, G. Bendas, G. Torri, 2012, Thrombosis research.

Non-Anticoagulant Heparins and Inhibition of Cancer

R. Sanderson, I. Vlodavsky, B. Casu, 2007, Pathophysiology of Haemostasis and Thrombosis.

Re-visiting the structure of heparin.

G. Torri, B. Casu, A. Naggi, 2015, Carbohydrate research.

Simple and specific assay of penicillins by IR spectrophotometry in deuterium oxide and dimethyl sulfoxide solutions.

P. Ventura, B. Casu*, 1974, Journal of pharmaceutical sciences.

SIMPLE AND SPECIFIC ASSAY OF PENICILLINS BY IR SPECTROPHOTOMETRY IN DEUTERIUM OXIDE AND DIMETHYL SULFOXIDE SOLUTIONS

P. Ventura, B. Casu*, 1974 .

Determination of Water in Carbohydrates by an Infrared Spectrophotometric Method

B. Casu, M. Reggiani, G. Gaglioppa, 1965 .

Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.

Benito Casu, Marco Presta, Annamaria Naggi, 2004, Glycobiology.

Stereoregular acyclic polyalcohols and polyacetates from cellulose and amylose

S. V. Meille, G. Torri, M. Terbojevich, 1985 .

Communications from research groups: Structure and conformation of polyalcohols and polyacids obtained from periodate oxyamylose and oxycellulose

G. Torri, V. Meille, A. Naggi, 1982 .

The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.

G. Torri, M. Petitou, J. Choay, 1981, The Biochemical journal.

Influence of glucose on production and N-sulfation of heparan sulfate in cultured adipocyte cells

L. Gotow, I. Goldberg, B. Casu, 2000, Molecular and Cellular Biochemistry.

Semisynthesis and Analysis of Lipophilically Modified Unfractionated and Low Molecular Mass Heparins

G. Torri, B. Casu, J. Harenberg, 1994, Seminars in thrombosis and hemostasis.

Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor.

U Lindahl, B. Casu, M Maccarana, 1994, The Journal of biological chemistry.

Configurational and conformational influences on the carbon-13 chemical shifts of some carbohydrates

B. Casu, A. Perlin, H. Koch, 1970 .

Carbon-13 and proton magnetic resonance spectra of D-glucose-13C

B. Casu, A. Perlin, B. Casu*, 1969 .

Conformation of Amylose and its Derived Products. I. Infrared Spectra of Amylose and its Oligomers in the Amorphous Solid Phase and in Solution

B. Casu, M. Reggiani, B. Casu*, 1966 .

A Simple Device for Qualitative Functional Group Analysis of Gas Chromatographic Effluents.

B. Casu, Luigi Cavallotti, B. Casu*, 1962 .

Conformation of heparin pentasaccharide bound to antithrombin III.

G. Torri, M. Petitou, M Petitou, 2001, The Biochemical journal.

Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins.

G. Torri, B. Casu, A. Naggi, 2001, Carbohydrate research.

"Supersulfated" heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties.

J. Maffrand, M. Donati, G. Torri, 1987, Biochemical pharmacology.

Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue.

G. Torri, M. Petitou, J. Choay, 1985, Biochemical and biophysical research communications.

Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5.

N. Razi, F. Tursi, G. Torri, 1994 .

Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.

R. Sasisekharan, R. Raman, G. Torri, 2008, Biochemistry.

Structural peculiarity and antithrombin binding region profile of mucosal bovine and porcine heparins.

M. Iacomini, G. Torri, B. Casu, 2016, Journal of pharmaceutical and biomedical analysis.

Unravelling structural information from complex mixtures utilizing correlation spectroscopy applied to HSQC spectra.

E. Yates, Davide Gaudesi, T. Rudd, 2013, Analytical chemistry.

1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives.

E. Yates, G. Torri, B. Casu, 1996, Carbohydrate research.

Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy.

G. Torri, B. Casu, M. Attolini, 1996, Arzneimittel-Forschung.

A novel heparan sulphate with high degree of N-sulphation and high heparin cofactor-II activity from the brine shrimp Artemia franciscana.

H. Nader, G. Torri, E. Santos, 2000, International journal of biological macromolecules.

Motional properties of E. coli polysaccharide K5 in aqueous solution analyzed by NMR relaxation measurements.

G. Torri, B. Casu, M. Guerrini, 1997, Carbohydrate research.

Structural characterization of low molecular weight heparins.

G. Torri, B. Casu, B. Casu*, 1999, Seminars in thrombosis and hemostasis.

Nonanticoagulant Actions of Glycosaminoglycans

Job Harenberg, Benito Casu, B. Casu, 2011, Springer US.

Magnetic bead protamine-linked microtiter assay for detection of heparin using iodinated low-molecular-mass heparin-tyramine.

G. Torri, B. Casu, J. Harenberg, 1995, Thrombosis research.

Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin.

C. Boudier, Davide Gaudesi, M. Lorenz, 2010, Journal of medicinal chemistry.

An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence.

C. Boudier, Davide Gaudesi, T. Rudd, 2013, The Biochemical journal.

Antithrombin-binding Octasaccharides and Role of Extensions of the Active Pentasaccharide Sequence in the Specificity and Strength of Interaction

C. Boudier, G. Torri, B. Casu, 2008, Journal of Biological Chemistry.

Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1.

L. Lay, G. Torri, B. Casu, 2002, Biochemical and biophysical research communications.

Heparin Dodecasaccharide Containing Two Antithrombin-binding Pentasaccharides STRUCTURAL FEATURES AND BIOLOGICAL PROPERTIES

C. Boudier, Davide Gaudesi, G. Torri, 2013 .

DIFFERENTIAL CALORIMETRIC STUDY OF POLYCYCLIC AROMATIC HYDROCARBONS

F. Casellato, C. Vecchi, A. Girelli, 1973 .

Involvement of Heparanase in Tumor Progression and Normal Differentiation

S. Minucci, C. Pisano, R. Eshel, 2003, Pathophysiology of Haemostasis and Thrombosis.

Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

G. Torri, B. Casu, A. Naggi, 2013, Analytical biochemistry.

Heparin-derived heparan sulfate mimics that modulate inflammation and cancer

G. Torri, B. Casu, A. Naggi, 2011 .

Chemical Derivatization as a Strategy to Study Structure-Activity Relationships of Glycosaminoglycans

G. Torri, B. Casu, A. Naggi, 2002, Seminars in thrombosis and hemostasis.

Preparation and Characterization of Deuterium-Labeled Glycosaminoglycans

G. Torri, A. Naggi, S. Magnaghi, 1994, Seminars in thrombosis and hemostasis.

Synthesis of Sulfated Glycosaminoglycans

G. Torri, B. Casu, A. Naggi, 2001 .

myeloma therapy The syndecan-1 heparan sulfate proteoglycan is a viable target for

B. Barlogie, L. Suva, J. Epstein, 2013 .

The impact of heparanase on cancer progression

C. Pisano, B. Brenner, I. Vlodavsky, 2009 .

Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide.

G. Torri, B. Casu, P. Oreste, 2001, Seminars in thrombosis and hemostasis.

Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligo-saccharides: NMR and force-field studies

Benito Casu, Dino R. Ferro, Massimo Ragazzi, 1986 .

Controversial glycosaminoglycan conformations

G. Torri, M. Petitou, J. Choay, 1986, Nature.

Non-Anticoagulant Heparins and Inhibition of Cancer

R. Sanderson, I. Vlodavsky, B. Casu*, 2007, Pathophysiology of Haemostasis and Thrombosis.

Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.

G. Bendas, G. Torri, A. Naggi, 2010, International journal of clinical pharmacology and therapeutics.

Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments

G. Torri, B. Casu, G. Cassinelli, 2013, Analytical and Bioanalytical Chemistry.

Studies on the Conformation of Heparin by 1H and 13C NMR Spectroscopy

B. Casu, A. Perlin, G. Gatti, 1979 .

Anti-Xa active heparin oligosaccharides.

G. Torri, M. Petitou, J. Choay, 1980, Thrombosis research.

Antiangiogenic heparin-derived heparan sulfate mimics

B. Casu, A. Naggi, B. Casu*, 2003 .

Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.

Benito Casu, Marco Presta, Sergio Penco, 2002, Biochemistry.

Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins.

G. Torri, B. Casu, M. Mantovani, 1986, Arzneimittel-Forschung.

Structure of heparins and their fragments.

B. Casu, B. Casu*, 1984, Nouvelle revue francaise d'hematologie.

Generation of "neoheparin" from E. coli K5 capsular polysaccharide.

M. Salmivirta, G. Torri, B. Casu, 2005, Journal of medicinal chemistry.

Active Conformations of Glycosaminoglycans. NMR Determination of the Conformation of Heparin Sequences Complexed with Antithrombin and Fibroblast Growth Factors in Solution

G. Torri, B. Casu, A. Naggi, 2002, Seminars in thrombosis and hemostasis.

Electrostatic Interactions between Human Leukocyte Elastase and Sulfated Glycosaminoglycans: Physiological Implications

A. Baici, B. Casu, G. Kostoulas, 1997, Biological chemistry.

Infrared spectra of glycosaminoglycans in deuterium oxide and deuterium chloride solution: Quantitative evaluation of uronic acid and acetamidodeoxyhexose moieties

B. Casu, A. Perlin, Giuseppe Scovenna, 1978 .

Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.

G. Torri, B. Casu, J. Harenberg, 2002, Seminars in thrombosis and hemostasis.

New insights on the specificity of heparin and heparan sulfate lyases from Flavobacterium heparinum revealed by the use of synthetic derivatives of K5 polysaccharide from E. coli. and 2-O-desulfated heparin

S. Shinjo, H. Nader, G. Torri, 1999, Glycoconjugate Journal.

Hydrogen bonding and conformation of glucose and polyglucoses in dimethyl-sulphoxide solution

G. Gallo, B. Casu, B. Casu, 1966 .

A novel computational approach to integrate NMR spectroscopy and capillary electrophoresis for structure assignment of heparin and heparan sulfate oligosaccharides.

R. Sasisekharan, R. Raman, G. Torri, 2002, Glycobiology.

Undersulfated and glycol-split heparins endowed with antiangiogenic activity.

D. Ribatti, G. Giannini, M. Rusnati, 2004, Journal of medicinal chemistry.

Conformations of the major residues in heparin. H-NMR sepctroscopic studies.

B. Casu, A. Perlin, G. Gatti, 1978, Biochemical and biophysical research communications.

Fractionation and characterization of glycosaminoglycans of mammalian origin.

J. Vercellotti, G. Torri, B. Casu, 1979, Pharmacological research communications.

A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides.

B. Casu, U. Gennaro, B. Casu*, 1975, Carbohydrate Research.

Glycosaminoglycans: Anticoagulant and Nonanticoagulant Actions: A Short History of Symposia Held at Villa Vigoni

G. Torri, B. Casu, J. Harenberg, 2014, Seminars in Thrombosis & Hemostasis.

Complexes of heparin with poly(alkylenimines): Competitive binding with methylene blue

P. Righetti, G. Torri, M. Legramandi, 1982 .

Synthesis and Physico-Chemical Properties of the Polyampholyte Chitosan 6-Sulfate

G. Torri, B. Casu, A. Naggi, 1986 .

Correlation of sulfate content and degree of carboxylation of heparin and related glycosaminoglycans with anticomplement activity. Relationships to the anticoagulant and platelet-aggregating activities.

F. Radaelli, G. Torri, B. Casu, 1979, Thrombosis research.

220 MHz spectra of heparin, chondroitins, and other mucopolysaccharides

G. R. Sanderson, B. Casu, L. Johnson, 1970 .

Conformation of the Unsaturated Uronic Acid Residues of Glycosamtnoglycan Disaccharides

H. Nader, G. Torri, C. Dietrich, 1993 .

Structure, Shape and Function of Glycosaminoglycans

B. Casu*, 1990 .

Chemically Modified Chitosans

S. Nishimura, K. Scheller, S. Hirano, 1986 .

Heparin structure.

B. Casu*, 1990, Haemostasis.